Achieve Life Sciences (NASDAQ:ACHV – Get Rating) is set to announce its earnings results after the market closes on Thursday, March 10th. Analysts expect the company to announce earnings of ($0.73) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Achieve Life Sciences stock opened at $7.15 on Thursday. The firm has a market cap of $67.59 million, a P/E ratio of -1.54 and a beta of 1.19. The business’s fifty day moving average is $7.73 and its two-hundred day moving average is $7.85. Achieve Life Sciences has a 52 week low of $6.55 and a 52 week high of $12.95.
Several institutional investors and hedge funds have recently modified their holdings of the company. LPL Financial LLC lifted its stake in shares of Achieve Life Sciences by 4.7% during the third quarter. LPL Financial LLC now owns 72,000 shares of the biopharmaceutical company’s stock valued at $612,000 after acquiring an additional 3,200 shares during the period. BlackRock Inc. increased its holdings in Achieve Life Sciences by 455.6% in the fourth quarter. BlackRock Inc. now owns 15,207 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 12,470 shares during the last quarter. Citadel Advisors LLC bought a new stake in Achieve Life Sciences in the fourth quarter valued at about $149,000. Geode Capital Management LLC increased its holdings in Achieve Life Sciences by 51.0% in the third quarter. Geode Capital Management LLC now owns 85,554 shares of the biopharmaceutical company’s stock valued at $727,000 after purchasing an additional 28,885 shares during the last quarter. Finally, Morgan Stanley increased its holdings in Achieve Life Sciences by 59.0% in the second quarter. Morgan Stanley now owns 139,200 shares of the biopharmaceutical company’s stock valued at $1,250,000 after purchasing an additional 51,654 shares during the last quarter. 35.86% of the stock is currently owned by institutional investors and hedge funds.
About Achieve Life Sciences (Get Rating)
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Achieve Life Sciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Achieve Life Sciences wasn’t on the list.
While Achieve Life Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.